Michelle Gilson
Stock Analyst at Morgan Stanley
(0)
# 4472
Out of 5,240 analysts
35
Total ratings
40.00%
Success rate
-13.24%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Vir Biotechnology | Upgrades: Overweight | 10 20 | 10.63 | 88.15% | 4 | Jan 9, 2025 | |
Homology Medicines | Maintains: Buy | 342 126 | n/a | n/a | 2 | Apr 6, 2022 | |
Corcept Therapeutics | Initiates Coverage On: Buy | 30 | 52.97 | -43.36% | 1 | Feb 2, 2022 | |
Sigilon Therapeutics | Maintains: Buy | 156 91 | n/a | n/a | 3 | Dec 23, 2021 | |
Rezolute | Maintains: Buy | 30 17 | 4.69 | 262.47% | 2 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 190 196 | 135 | 45.19% | 5 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 48 45 | 17.7 | 154.24% | 3 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 72 76 | 8.9 | 753.93% | 4 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 95 91 | 63.73 | 42.79% | 8 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 40 | n/a | n/a | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 38 23 | n/a | n/a | 2 | Aug 23, 2019 |